Evidence map›Paper›PMID 42900363›Full record

ArticleAnnals of hematology2026

Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40-65: a multicenter retrospective study.

Xiaohui Xiao, Guiping Chen, Cong Xu, Liangliang Wu, Xiaoyan Liu, Ming Zhou, Xiaowei Chen, Ruiqing Zhou, Wenjian Mo, Yumiao Li and 4 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiaohui Xiao *Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Guiping Chen *Department of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Cong Xu *Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Liangliang WuDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Xiaoyan LiuDepartment of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Ming ZhouDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Xiaowei ChenDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Ruiqing ZhouDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Wenjian MoDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Yumiao LiDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Shilin XuDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Yuping ZhangDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China. jnzhangyuping@163.com.
Dongjun LinDepartment of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China. lindongJun0168@163.com.
Shunqing WangDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China. eywangshq@scut.edu.cn.ORCID http://orcid.org/0000-0001-9418-4901

Funding

2019 Annual Research Project of the China Marrow Donor Program No. CMDO201902Innovative Clinical Technique of Guangzhou No. 2023C-GX01National Key R&D program of China 2023YFA1800100National Natural Science Foundation of China 82400245Sanming Project of Medicine in Shenzhen SZSM202411022Shenzhen Science and Technology Program JCYJ20230807110405012
6 · The paper itself

Abstract

Immunosuppressive therapy (IST) plus eltrombopag (EPAG) (IST+EPAG) is the preferred first-line treatment for severe aplastic anemia (SAA) patients over 40 years. However, direct comparison between IST+EPAG and upfront haploidentical hematopoietic stem cell transplantation (HID-HSCT) in this population remains limited. We retrospectively analyzed 123 newly diagnosed SAA patients aged 40-65 who received first-line HID-HSCT (n = 67) or IST+EPAG (n = 56) between 2016 and 2024. Hematological response, survival, and safety were compared. The HID-HSCT group demonstrated superior complete response (CR) rates at 3 months (17.9% vs. 5.4%), 6 months (44.8% vs. 17.9%), and 12 months (64.2% vs. 33.9%) (all P < 0.001). The 3-year overall survival (OS) was comparable between the HID-HSCT and IST+EPAG groups (78.0% vs. 80.3%, P = 0.662), and a landmark analysis conditional on survival to 6 months confirmed comparable subsequent 3-year OS (92.2% vs. 88.9%, P = 0.616). Meanwhile, the 3-year failure-free survival (FFS) was significantly higher in the HID-HSCT group among patients aged 40-49 (82.9% vs. 60.1%, P = 0.045), whereas no difference was observed in those aged 50-65 (P = 0.984). HID-HSCT may offer more durable benefits in selected SAA patients aged 40-49, while its advantage over IST+EPAG is not evident in patients aged 50-65.

Indexed as

Anemia, AplasticBenzoatesHematopoietic Stem Cell TransplantationHydrazinesImmunosuppression TherapyImmunosuppressive AgentsPyrazolesTransplantation, HaploidenticalAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateBenzoateseltrombopagHydrazinesImmunosuppressive AgentsPyrazolesHaploidentical hematopoietic stem cell transplantationImmunosuppressive therapySevere aplastic anemia

Identifiers

PMID42900363
PMCPMC13683484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.